- This event has passed.
Presenter(s): Julie Kmiec, DO
About the webinar: This lecture will discuss the history of the rise of opiate addiction in the United States and the Harrison Narcotics Act that was enacted in 1914 to try to control use of narcotics, as well as case law from that era. The early treatment of opiate addiction with be reviewed leading to the development of methadone for maintenance treatment of heroin addiction. Subsequent changes in legislation allowing for maintenance treatment with methadone and later, buprenorphine will also be explored.
At the conclusion of this activity participants should be able to:
- Discuss the rise in the use of and addiction to opiates in the 19th and early 20th centuries.
- Cite legislation and case law that has shaped the treatment of opioid use disorder over the past century.
- Describe the Dole & Nyswander (1965) clinical trial of methadone for treatment of heroin addiction.
- Summarize how the Drug Addiction Treatment Act of 2000 further allowed treatment of opioid use disorder.
- Discuss the Comprehensive Addiction Recovery Act of 2016 and its impact on treatment on opioid use disorders.
How to obtain your Certificate of Completion:
Thank you for viewing our archived webinar. In order to document your participation in the training, please follow the steps below to obtain your Certificate of Completion.
- Click the “Watch Now” button above and follow the on-screen prompts.
- View the recorded webinar and return to the web page that listed the webinar recording link.
- Click “Continue” to move to the next page.
- Select “Yes” to attest that you have viewed the recording in its entirety.
- Click “Complete Course” and you will be directed to our thank you page.
- Click the “Click here to continue” link to complete the evaluation.
- Upon completion of the evaluation, you will receive your Certificate of Completion via email.
- If you have any questions or you do not receive your certificate, please email or call (855) 227-2776.
Note: This archive webinar is not designated for AMA PRA Category 1 Credit™.